S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.04 (-1.73%)
MSFT   312.36 (-1.63%)
META   298.85 (-0.66%)
GOOGL   128.30 (-2.14%)
AMZN   127.68 (-2.73%)
TSLA   246.57 (-0.17%)
NVDA   422.54 (+0.08%)
NIO   8.48 (+1.56%)
BABA   86.22 (-1.15%)
AMD   96.13 (-1.28%)
T   15.04 (-0.13%)
F   12.53 (-0.40%)
MU   68.36 (-0.32%)
CGC   0.94 (-0.31%)
GE   110.18 (-1.38%)
DIS   80.47 (-0.67%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.11 (+0.42%)
NFLX   381.22 (-0.93%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.04 (-1.73%)
MSFT   312.36 (-1.63%)
META   298.85 (-0.66%)
GOOGL   128.30 (-2.14%)
AMZN   127.68 (-2.73%)
TSLA   246.57 (-0.17%)
NVDA   422.54 (+0.08%)
NIO   8.48 (+1.56%)
BABA   86.22 (-1.15%)
AMD   96.13 (-1.28%)
T   15.04 (-0.13%)
F   12.53 (-0.40%)
MU   68.36 (-0.32%)
CGC   0.94 (-0.31%)
GE   110.18 (-1.38%)
DIS   80.47 (-0.67%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.11 (+0.42%)
NFLX   381.22 (-0.93%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.04 (-1.73%)
MSFT   312.36 (-1.63%)
META   298.85 (-0.66%)
GOOGL   128.30 (-2.14%)
AMZN   127.68 (-2.73%)
TSLA   246.57 (-0.17%)
NVDA   422.54 (+0.08%)
NIO   8.48 (+1.56%)
BABA   86.22 (-1.15%)
AMD   96.13 (-1.28%)
T   15.04 (-0.13%)
F   12.53 (-0.40%)
MU   68.36 (-0.32%)
CGC   0.94 (-0.31%)
GE   110.18 (-1.38%)
DIS   80.47 (-0.67%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.11 (+0.42%)
NFLX   381.22 (-0.93%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.04 (-1.73%)
MSFT   312.36 (-1.63%)
META   298.85 (-0.66%)
GOOGL   128.30 (-2.14%)
AMZN   127.68 (-2.73%)
TSLA   246.57 (-0.17%)
NVDA   422.54 (+0.08%)
NIO   8.48 (+1.56%)
BABA   86.22 (-1.15%)
AMD   96.13 (-1.28%)
T   15.04 (-0.13%)
F   12.53 (-0.40%)
MU   68.36 (-0.32%)
CGC   0.94 (-0.31%)
GE   110.18 (-1.38%)
DIS   80.47 (-0.67%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.11 (+0.42%)
NFLX   381.22 (-0.93%)
NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Forecast, Price & News

$0.38
+0.01 (+1.76%)
(As of 12:45 PM ET)
Compare
Today's Range
$0.36
$0.38
50-Day Range
$0.37
$0.66
52-Week Range
$0.35
$1.70
Volume
241,112 shs
Average Volume
788,739 shs
Market Capitalization
$43.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Precision BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
699.4% Upside
$3.00 Price Target
Short Interest
Healthy
1.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
0.27mentions of Precision BioSciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.77) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

396th out of 961 stocks

Biological Products, Except Diagnostic Industry

62nd out of 161 stocks


DTIL stock logo

About Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

DTIL Price History

DTIL Stock News Headlines

Precision BioSciences' (DTIL) Buy Rating Reaffirmed at HC Wainwright
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
What 4 Analyst Ratings Have To Say About Precision BioSciences
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
BTIG Sticks to Their Buy Rating for Precision BioSciences (DTIL)
The Latest Analyst Ratings for Precision BioSciences
See More Headlines
Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

DTIL Company Calendar

Last Earnings
8/04/2023
Today
9/26/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DTIL
Fax
N/A
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+699.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-111,640,000.00
Net Margins
-192.10%
Pretax Margin
-192.10%

Debt

Sales & Book Value

Annual Sales
$25.10 million
Book Value
$0.54 per share

Miscellaneous

Free Float
110,468,000
Market Cap
$43.19 million
Optionable
Not Optionable
Beta
1.31
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Michael Amoroso (Age 45)
    Pres, CEO & Director
    Comp: $979.04k
  • Mr. John Alexander Kelly R.Ph. (Age 56)
    Chief Financial Officer
    Comp: $623.58k
  • Mr. Dario Scimeca (Age 47)
    Gen. Counsel & Sec.
    Comp: $576.43k
  • Dr. Derek Jantz Ph.D. (Age 47)
    Co-Founder & Chief Science Advisor
  • Dr. Jefferson J. Smith Ph.D. (Age 50)
    Co-Founder & Chief Research Officer
  • Mr. Shane Barton (Age 52)
    VP, Corp. Controller & Principal Accounting Officer
  • Mei Burris
    Director of Investor Relations & Fin.
  • Mr. Bruce Stevens
    VP of Quality & Compliance
  • Maurissa Messier
    Sr. Director of Corp. Communications
  • Ms. Juli Blanche
    Chief People Officer













DTIL Stock - Frequently Asked Questions

Should I buy or sell Precision BioSciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DTIL shares.
View DTIL analyst ratings
or view top-rated stocks.

What is Precision BioSciences' stock price forecast for 2023?

3 brokerages have issued 12-month price targets for Precision BioSciences' stock. Their DTIL share price forecasts range from $2.00 to $4.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 699.4% from the stock's current price.
View analysts price targets for DTIL
or view top-rated stocks among Wall Street analysts.

How have DTIL shares performed in 2023?

Precision BioSciences' stock was trading at $1.19 at the beginning of the year. Since then, DTIL shares have decreased by 68.5% and is now trading at $0.3753.
View the best growth stocks for 2023 here
.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,640,000 shares, an increase of 62.4% from the August 15th total of 1,010,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is presently 1.5 days. Approximately 1.8% of the company's shares are short sold.
View Precision BioSciences' Short Interest
.

When is Precision BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our DTIL earnings forecast
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) issued its earnings results on Friday, August, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.13. The company had revenue of $19.79 million for the quarter, compared to analyst estimates of $6.58 million. Precision BioSciences had a negative trailing twelve-month return on equity of 163.24% and a negative net margin of 192.10%.

What ETF holds Precision BioSciences' stock ?

Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Great Point Partners LLC (6.49%), JPMorgan Chase & Co. (1.81%), Stifel Financial Corp (1.70%), Renaissance Technologies LLC (1.49%), CHI Advisors LLC (1.39%) and BlackRock Inc. (1.06%). Insiders that own company stock include Alan List, Dario Scimeca, David S Thomson, David S Thomson, Derek Jantz, John Alexander Kelly, Matthew R Kane, Matthew R Kane, Michael Amoroso and Vince Craig Hopkin.
View institutional ownership trends
.

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $0.38.

How much money does Precision BioSciences make?

Precision BioSciences (NASDAQ:DTIL) has a market capitalization of $43.19 million and generates $25.10 million in revenue each year. The company earns $-111,640,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

How many employees does Precision BioSciences have?

The company employs 192 workers across the globe.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The official website for the company is www.precisionbiosciences.com. The company can be reached via phone at (919) 314-5512 or via email at jwong@bplifescience.com.

This page (NASDAQ:DTIL) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -